Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Relapse in, and recovery from, schizophrenia has been acknowledged since the disease was first described. In this review the authors summarize the long-term (>100 years) data on relapse and recovery in schizophrenia by reviewing the extant older and modern relevant literature. The authors systematically question the utility of pharmacological and nonpharmacological interventions, with an emphasis on first episode nonaffective psychosis. The method used is a narrative review of earlier meta-analytic and systematic reviews. Antipsychotic medication discontinuation studies suggest a role for prophylactic maintenance treatment in the majority of people with schizophrenia, despite recent debate on this subject. The authors conclude that long-term outcomes, including relapse and recovery rates, have improved in the last 100 years, though prospectively identifying those people who do not require long-term antipsychotic treatment has not yet been possible. Data also suggests that interventions and outcomes during the first 5 years of the disease can influence the long-term schizophrenia trajectory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, neurobehavioural disorders tend to be chronic and relapse even after a positive response to treatment in the short term.20,21”
From Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders (2021) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,343
A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes
Wykes, T., Huddy, V., Cellard, C., McGurk, S. R., & Czobor, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10060855 · Cited by 1,693
Howes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,132
Recovery from psychotic illness: A 15- and 25-year international follow-up study
Harrison, G., Hopper, K., Craig, T., Laska, E., Siegel, C., Wanderling, J., Dube, K. C., Ganev, K., Giel, R., Der Heiden, W. A., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.6.506 · Cited by 1,030
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
A Systematic Review and Meta-Analysis of Recovery in Schizophrenia
Jaaskelainen, E., Juola, P., Hirvonen, N., McGrath, J. J., Saha, S., Isohanni, M., Veijola, J., & Miettunen, J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs130 · Cited by 907
Review: Suicide and schizophrenia: a systematic review of rates and risk factors
Hor, K., & Taylor, M. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810385490 · Cited by 853
Self-citationCorrell, C. U., Galling, B., Pawar, A., Krivko, A., Bonetto, C., Ruggeri, M., Craig, T. J., Nordentoft, M., Srihari, V. H., Guloksuz, S., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0623 · Cited by 826
Neuroleptics and the Natural Course of Schizophrenia
Wyatt, R. J. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.2.325 · Cited by 787
Research works printed but not linked: 1
- Kraepelin E. Dementia praecox. Cambridge University Press, 1987.
Cited by
Sampogna, G., Vincenzo, M. D., Giuliani, L., Menculini, G., Mancuso, E., Arsenio, E., Cipolla, S., Rocca, B. D., Martiadis, V., Signorelli, M. S., et al. (2023) · Brain Sciences · doi:10.3390/brainsci13111577 · Cited by 84
“In particular, pharmacological drug interventions represent the cornerstone in the management of schizophrenia and other psychotic spectrum disorders [24–26].”
BackgroundNew Developments in the Treatment of Schizophrenia: An Expert Roundtable
Kantrowitz, J. T., Correll, C. U., Jain, R., & Cutler, A. J. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad011 · Cited by 62
“Median recovery rates have remained stable or even decreased over time from before 1941 to after the introduction of atypical antipsychotics, with only 10%–20% of patients fully recovering (Jaaskelainen et al., 2013; Taylor and Jauhar, 2019; Huxley et al., 2021).”
Lin, D., Joshi, K., Keenan, A., Shepherd, J., Bailey, H. M. L., Berry, M., Wright, J., Meakin, S., Benson, C. J., & Kim, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.695672 · Cited by 55
“Patients with a relapsing course of disease are less likely to engage in long-term relationships (22).”
BackgroundPrevalence of treatment resistance and clozapine use in early intervention services
Stokes, I., Griffiths, S. L., Jones, R., Everard, L., Jones, P. B., Fowler, D. G., Hodgekins, J., Amos, T., Freemantle, N., Sharma, V. K., et al. (2020) · BJPsych Open · doi:10.1192/bjo.2020.89 · Cited by 45
Lenze, E. J., Nicol, G. E., Barbour, D. L., Kannampallil, T., Wong, A. W. K., Piccirillo, J., Drysdale, A. T., Sylvester, C. M., Haddad, R., Miller, J. P., et al. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.200042 · Cited by 43
Kane, J. M., Harary, E., Eshet, R., Tohami, O., Weiser, M., Leucht, S., Wagner, A. M., Sharon, N. A., Davis, G. L., Suett, M., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00288-2 · Cited by 36
Vita, A., Barlati, S., Deste, G., Nibbio, G., Penn, D. L., Pinkham, A. E., McIntyre, R. S., & Harvey, P. D. (2023) · Psychological Medicine · doi:10.1017/s0033291723002106 · Cited by 36
“…is an essential first step in the rehabilitation processes (Vita & Barlati, 2018), and symptom exacerbations and resulting relapses represent one of the most important limiting factors of functional and personal recovery (Jääskeläinen et al., 2013; Maj et al., 2021; Taylor & Jauhar, 2019).”
BackgroundFear of relapse in schizophrenia: a mixed-methods systematic review
Zukowska, Z., Allan, S., Eisner, E., Ling, L., & Gumley, A. I. (2022) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-022-02220-2 · Cited by 39
“Although relapse is considered common [5], around 20% of patients never relapse [50].”
BackgroundMcCutcheon, R. A., Taylor, D. M., Rubio, J. M., Nour, J., Pillinger, T., Murray, R. M., & Jauhar, S. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad139 · Cited by 27
Self-citationAbdullah-Koolmees, H., Nawzad, S., Egberts, T. C. G., Vuyk, J., Gardarsdóttir, H., & Heerdink, E. R. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211027449 · Cited by 26
Challenges and Strategies for the Recruitment of Patients With Schizophrenia in a Research Setting
Deckler, E., Ferland, M., Brazis, S., Mayer, M., Carlson, M., & Kantrowitz, J. T. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac058 · Cited by 22
“Even with the best available treatments, only 10% to 20% of patients with schizophrenia recover fully (Jaaskelainen et al., 2013; Taylor and Jauhar, 2019).”
Fusar‐Poli, P., Lai, S., Forti, M. D., Iacoponi, E., Thornicroft, G., McGuire, P. K., & Jauhar, S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.577110 · Cited by 25
“This change over time may also reflect side-effects of antipsychotics in a significant number of patients, as well as more acute presentations at first onset of illness (the first 5 years of illness being associated with greater variability in illness acuity (40)).”
BackgroundSelf-citationStiernborg, M., Prast‐Nielsen, S., Melas, P. A., Skott, M., Millischer, V., Boulund, F., Forsell, Y., & Lavebratt, C. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.01.218 · Cited by 17
“…the early phase of SSD. Individuals with a diagnosis of SCZ have on average 20 years shortened life expectancy mainly due to cardiovascular comorbidities, and around 20% of the individuals experiencing an acute psychosis recover during their lifetime (Nielsen et al., 2021; Taylor & Jauhar, 2019).”
BackgroundFamily environment and depressive episode are associated with relapse after first‐episode psychosis
da Silva, A. H. S., de Freitas, L. A., Shuhama, R., Del‐Ben, C. M., Vedana, K. G. G., Martin, I. D. S., & Zanetti, A. C. G. (2021) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12735 · Cited by 17
Cuesta, M. J., Sánchez-Torres, A. M., Moreno-Izco, L., de Jalón, E. G., Gil‐Berrozpe, G. J., Zarzuela, A., Peralta, V., Ballesteros, A., Fañanás, L., Hernández, R., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114933 · Cited by 20
Kantrowitz, J. T. (2021) · CNS Drugs · doi:10.1007/s40263-021-00864-3 · Cited by 17
Antipsychotic utilisation and persistence in Australia: A nationwide 5-year study
Taylor, M., Dangelo-Kemp, D., Liu, D., Kisely, S. R., Graham, S., Hartmann, J., & Colman, S. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211051618 · Cited by 15
“Antipsychotic medication remains the cornerstone of treatment for schizophrenia given it reduces relapse (Taylor and Jauhar, 2019), with most guidelines recommending maintenance antipsychotics for at least a year after a first episode of psychosis (FEP) and for over 2 years after a relapse…”
BackgroundSelf-citationJauhar, S., & Lawrie, S. M. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00293-5 · Cited by 16
Self-citationJones, R., Upthegrove, R., Price, M. J., Pritchard, M., Chandan, J. S., Legge, S. E., & MacCabe, J. H. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221103353 · Cited by 12
Bornheimer, L. A., Martz, M. E., Suzuki, T., Tso, I. F., Burton, C. Z., Verdugo, J. L., Grove, T. B., Heitzeg, M. M., & Taylor, S. F. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac015 · Cited by 11
Nyttingnes, O., Benth, J. Š., Hofstad, T., & Rugkåsa, J. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04584-4 · Cited by 11
“These seem to be relevant concerns, as many patients with psychotic disorders experience relapse [29], chronicity [30], and because patients with SMDs on average die 10–30 years younger than their peers [31].”
BackgroundEarly intervention in psychosis during the COVID-19 pandemic: Maudsley recommendations
Jauhar, S., Lai, S., Bonoldi, I., de Pablo, G. S., Forti, M. D., Alameda, L., Donocik, J. G., Iacoponi, E., Spencer, T. J., Haege, B., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.005 · Cited by 10
Self-citationSchizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
Al-Kuraishy, H. M., Mohammed, H. A., Sulaiman, G. M., Jabir, M. S., Al-Gareeb, A. I., & Albuhadily, A. K. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116575 · Cited by 10
Corbeil, O., Essiambre, A., Béchard, L., Roy, A.-A., Huot‐Lavoie, M., Brodeur, S., Chandrasena, R. D., Thériault, C., Crocker, C. E., Melun, J.-P., et al. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221136021 · Cited by 7
Yoon, J., Mayer, M., Berro, T., Brazis, S., & Kantrowitz, J. T. (2025) · Pharmaceutical Medicine · doi:10.1007/s40290-024-00545-8 · Cited by 6
“Despite the availability of multiple antipsychotics, about 80% of individuals do not recover fully [3], leading to many patients living with poor functional outcomes.”
Hassib, L., Kanashiro, A., Pedrazzi, J. F. C., Vercesi, B. F., Higa, S., Arruda, Í., Soares, Y., de Souza, A. P., Jordão, A. A., Guimarães, F. S., et al. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100923 · Cited by 9
Griffiths, S. L., & Birchwood, M. J. (2020) · Medicina · doi:10.3390/medicina56120638 · Cited by 6
Aftab, A. (2024) · Psychological Medicine · doi:10.1017/s003329172400312x · Cited by 5
“Taylor and Jauhar (2019) reviewed recovery rates over the past century, noting that even in the pre-antipsychotic era, around 15% to 20% of patients experienced prolonged periods of recovery, as seen in studies like those by Langfeld (1937) and Malamud and Render (1939).”
Disentangling relapse and adherence in psychosis
McCutcheon, R. A. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30310-2 · Cited by 4
Liu, F., Qiao, W., Yuan, X., Hei, G., Li, X., Zhang, Y., Song, X., & Zhang, D. (2024) · Cambridge Prisms Global Mental Health · doi:10.1017/gmh.2024.49 · Cited by 5
“These individuals who have a relapsing course of illness are less likely to marry or sustain long relationships (Taylor and Jauhar, 2019) and are linked to an increased risk of suicidal behavior (Rina et al., 2011).”
Neuroimaging alterations and relapse in early-stage psychosis
Mihaljevic, M. M., Nagpal, A., Etyemez, S., Narita, Z. C., Ross, A., Schaub, R., Cascella, N. G., Coughlin, J. M., Nestadt, G., Nucifora, F. C., et al. (2024) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.230115 · Cited by 4
“9 Relapse is a complex condition to which many factors, such as AP medication cessation, substance abuse, and stressful life events, may contribute (Taylor and Jauhar, 2019).”
BackgroundShould clozapine be offered as a second-line antipsychotic?
Butler, E., Stratford, M., & Jauhar, S. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00440-1 · Cited by 3
Self-citationA proposal definition criteria for psychotic relapse: Filling the gap for real-world studies
Migoya-Borja, M., Martínez‐Alés, G., Barrigón, M. L., Palomar-Ciria, N., Cegla-Schvartzman, F., & Baca‐García, E. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.11.003 · Cited by 3
Psychosocial approaches in schizophrenia
Korkmaz, U., & Hocaoğlu, Ç. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1006593 · Cited by 4
Jirapramukpitak, T., & Supanya, S. (2025) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2025.100617 · Cited by 3
Compliance and insight as factors of recovery in patients with schizophrenia spectrum disorders
Karpenko, O. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212201241 · Cited by 3
Louie, K., Jauhar, S., Rubio, J., Brand, B. A., Pillinger, T., Howes, O. D., & McCutcheon, R. A. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00225-7 · Cited by 2
Self-citationSchizophrenia and Related Psychoses
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg001.pub2 · Cited by 2
Foreman, D. M. (2024) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.230137 · Cited by 1
“14 Both psychosis and the drugs used to manage it have associated risks of harm, so balancing these risks is essential to ethical trial design.”
BackgroundMood and Psychosis: Limits and Overlapping between Psychotic Disorders and Mood Disorders
Gaughran, F. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.009 · Cited by 1
Hao, J., Starzer, M. S. K., Hansen, H. G., Hjorthøj, C. R., Nordentoft, M., Veling, W., Albert, N., & Alizadeh, B. Z. (2026) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-026-03043-1 · Cited by 1
“Furthermore, achieving sustained clinical recovery in the mid-to long-term still poses a considerable challenge [90], as the individuals might experience intermittent symptoms and/or relapse [88].”
Teixeira, J. M., Amorim, G., & Pires, A. C. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.992256 · Cited by 2
Recovery in der Behandlung der Schizophrenie: Vision oder Realität?
Adorjan, K., & Falkai, P. (2019) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-019-2300-y · Cited by 2
“(3) Bei ausreichendem erapieansprechen und rechtzeitigem Beginn der psychopharmakologischen Behandlung kann bei der Erstmanifestation der Erkrankung eine Symptomremission und ein Recovery sogar bei 60 – 70 % der Patienten erreicht werden [26, 27].”
BackgroundOrtega, L. (2020) · Rovira & Virgili repository · Cited by 2
(2024) · Cambridge Prisms Global Mental Health · doi:10.1017/gmh.2024.49.pr3
IMPLICACIONES DEL ESTRÉS SUBJECTIVO EN LOS ASPECTOS METABÓLICOS DE JÓVENES CON UNA PSICOSIS TEMPRANA
Ortega Sanz, L. (2020) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Lüdtke, T. (2021) · NVA (Nasjonalt vitenarkiv)
Villar, J. D., Stavrum, A.-K., Spíndola, L., Zayats, T., Tesfaye, M., Bjella, T., Steen, N. E., Melle, I. S., Andreassen, O. A., Steen, V. W., et al. (2026) · Translational Psychiatry · doi:10.21203/rs.3.rs-8309238/v1
Understanding Schizophrenia: A Bayesian Symptom Network Approach
Buchwald, K. (2025) · Tuwhera (Auckland University of Technology)
Contemporary Perspectives on Persons with Mental Disorders in Forensic Legal Practice
Rzayev, T. (2026) · Azərbaycan Psixiatriya Jurnalı · doi:10.66642/vthn4831
Predictors of life engagement in patients with schizophrenia
Kornetova, E. G., Алексеевич, Г. С., Александрович, П. Д., & Корнетов, А. Н. (2026) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202612605183
Mayer, M., Choo, T.-H. J., Javitt, D. C., & Kantrowitz, J. T. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02467-2
Rodríguez, J. M. M., Collazos, F., Martínez-Raga, J., de Blas-Soto, J., Bolívar-Perálvarez, M., & Gutiérrez-Rojas, L. (2026) · Actas Españolas de Psiquiatría · doi:10.62641/aep.v54i4.2145
“As relapses are common, continued antipsychotic treatment is recommended to maintain symptoms remission [70,71].”
Wunha, N., Maksuk, S., Pilakanta, S., Jekpoo, S., Apiwatnakorn, P., Taylor, M., Boonlue, T., Wongpakaran, T., & Jenraumjit, R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1899860
“Nonadherence to antipsychotic therapy among patients with schizophrenia may consequently lead to relapse of the illness (Taylor and Jauhar, 2019; Chaiphet, 2024).”
Self-citationบทบาทพยาบาลเพื่อส่งเสริมการฟื้นคืนสู่สุขภาวะของผู้ป่วยจิตเภทเรื้อรังในชุมชน
Piyaphattanuschai, T., Chuektong, C., & Chuaktong, S. (2026) · Journal of Prachomklao College of Nursing, Phetchaburi Province
Metadata
- Authors
- Taylor, M., & Jauhar, S.
- Affiliations
- The University of Queensland (AU)
- King's College London (GB)
- Corresponding author
- Taylor, Mark
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2019-01
- Volume
- 9
- Pages
- 2045125319870033-2045125319870033
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC6732843
- OpenAlex
- W2971922960
- Cited by
- 51
- References
- 62
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 8 · 2023: 6 · 2022: 9 · 2021: 10 · 2020: 4 · 2019: 1
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, first-episode psychosis, relapse, recovery, long-term outcomes, antipsychotic drugs, antipsychotic discontinuation, non-affective psychosis, treatment outcomes over time
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.